Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Maintains Buy on Satsuma Pharmaceuticals, Lowers Price Target to $3

HC Wainwright & Co. analyst Oren Livnat maintains Satsuma Pharmaceuticals (NASDAQ:STSA) with a Buy and lowers the price target from $18 to $3.
byBenzinga Newsdesk
November 15, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

HC Wainwright & Co. analyst Oren Livnat maintains Satsuma Pharmaceuticals (NASDAQ:STSA) with a Buy and lowers the price target from $18 to $3.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts